Ally Bridge Group NY LLC Makes New Investment in Perspective Therapeutics, Inc. $CATX

Ally Bridge Group NY LLC acquired a new position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 926,557 shares of the company's stock, valued at approximately $3,864,000. Perspective Therapeutics comprises 3.1% of Ally Bridge Group NY LLC's investment portfolio, making the stock its 14th biggest holding. Ally Bridge Group NY LLC owned 0.81% of Perspective Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Commodore Capital LP purchased a new position in shares of Perspective Therapeutics during the first quarter valued at approximately $26,424,000. Affinity Asset Advisors LLC raised its position in Perspective Therapeutics by 954.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company's stock valued at $13,196,000 after buying an additional 2,864,582 shares during the last quarter. Spruce Street Capital LP bought a new position in Perspective Therapeutics during the 1st quarter valued at $10,955,000. Opaleye Management Inc. bought a new position in Perspective Therapeutics during the 4th quarter valued at $3,257,000. Finally, Yu Fan bought a new position in Perspective Therapeutics during the 1st quarter valued at $4,401,000. Institutional investors own 54.66% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Wedbush reiterated an "outperform" rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, May 5th. BTIG Research reissued a "buy" rating on shares of Perspective Therapeutics in a research report on Friday. Eight analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $12.62.

Perspective Therapeutics Stock Up 1.8%

Shares of CATX opened at $2.87 on Wednesday. The stock has a 50 day moving average of $3.27 and a 200 day moving average of $3.90. Perspective Therapeutics, Inc. has a 12 month low of $1.96 and a 12 month high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.04. The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.16 million. Perspective Therapeutics had a negative return on equity of 42.33% and a negative net margin of 17,982.69%. Research analysts predict that Perspective Therapeutics, Inc. will post -1.1 earnings per share for the current year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.